Literature DB >> 25979399

Nasopharyngeal carcinoma.

Sophia C Kamran1, Nadeem Riaz2, Nancy Lee3.   

Abstract

Nasopharyngeal carcinoma is uncommon in the United States, with only 0.2 to 0.5 cases per 100,00 people; this is in contrast to southern China and Hong Kong, where the incidence is 25 to 50 per 100,000 people. There is a potential link between Epstein-Barr virus and the development of nasopharyngeal carcinoma. Radiotherapy alone as a single modality leads to similar 10-year survival rates in United States, Denmark, and Hong Kong (34%, 37%, and 43%, respectively). Multiple studies have shown an advantage to concurrent chemoradiation in the treatment of advanced disease. Radiation therapy remains the mainstay of salvage therapy, and modern techniques have allowed clinicians to achieve adequate local control without excessive toxicity.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  EBV molecular biology; Epstein-Barr virus; Head and neck cancer; Nasopharyngeal carcinoma

Mesh:

Year:  2015        PMID: 25979399     DOI: 10.1016/j.soc.2015.03.008

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  60 in total

Review 1.  The evolution of nasopharyngeal carcinoma staging.

Authors:  Rui Guo; Yan-Ping Mao; Ling-Long Tang; Lei Chen; Ying Sun; Jun Ma
Journal:  Br J Radiol       Date:  2019-07-12       Impact factor: 3.039

2.  [Development and validation of a multivariate risk model for distant metastasis of advanced nasopharyngeal carcinoma].

Authors:  Lu Zhang; Xiaoning Luo; Xiaokai Mo; Wenhui Huang; Changhong Liang; Shuixing Zhang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-12-30

3.  Effects of gene polymorphisms in the endoplasmic reticulum stress pathway on clinical outcomes of chemoradiotherapy in Chinese patients with nasopharyngeal carcinoma.

Authors:  Xiao-Bin Guo; Wan-le Ma; Li-Juan Liu; Yu-Ling Huang; Jing Wang; Li-Hua Huang; Xiang-Dong Peng; Ji-Ye Yin; Jin-Gao Li; Shao-Jun Chen; Guo-Ping Yang; Hui Wang; Cheng-Xian Guo
Journal:  Acta Pharmacol Sin       Date:  2017-02-20       Impact factor: 6.150

4.  miR-944 inhibits cell migration and invasion by targeting MACC1 in nasopharyngeal carcinoma.

Authors:  Juanjuan Ji; Yi Peng; Tao Niu; Yunhong Lin; Yan Lin; Xudong Li; Xiaoguang Wu; Zhiyong Huang; Ling Zhong; Shinan Zhang
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

5.  LncRNA CCAT1 modulates the sensitivity of paclitaxel in nasopharynx cancers cells via miR-181a/CPEB2 axis.

Authors:  Qiaosu Wang; Wenjing Zhang; Shaojuan Hao
Journal:  Cell Cycle       Date:  2017-03-30       Impact factor: 4.534

6.  [Long non-coding RNA XIST modulates cisplatin resistance by altering PDCD4 and Fas-Lexpressions in human nasopharyngeal carcinoma HNE1 cells in vitro].

Authors:  Hao Wang; Wei Li; Guolin Tan
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-03-30

7.  Expression of chemokine receptor CXCR4 is closely correlated with clinical outcome in human nasopharyngeal carcinoma.

Authors:  Hengmin Tao; Yumei Wei; Congan Wang; Kun Yang; Wei Huang; Haitao Liu; Baosheng Li
Journal:  Tumour Biol       Date:  2015-11-26

8.  Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: Converging incidence in males and females.

Authors:  Lindsey A Torre; Ann M Goding Sauer; Moon S Chen; Marjorie Kagawa-Singer; Ahmedin Jemal; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2016-01-14       Impact factor: 508.702

9.  HOXA11-AS induces cisplatin resistance by modulating the microRNA-98/PBX3 axis in nasopharyngeal carcinoma.

Authors:  Haineng Li; Jia Huang; Sa Yu; Hangbo Li; Yan Zhou; Qingwei Wu
Journal:  Oncol Lett       Date:  2021-04-26       Impact factor: 2.967

10.  Network Pharmacology Reveals Polyphyllin II as One Hit of Nano Chinese Medicine Monomers against Nasopharyngeal Carcinoma.

Authors:  Meng-Zhe Yang; Bei-Bei Zhang; Jian-Chun Huang; Xian-Yu Bai; Zhen-Qiang Liang; Xiang Yi; Ning Xu; Yuan-Jiao Huang; Ai-Jun Jiao
Journal:  Bioinorg Chem Appl       Date:  2021-04-29       Impact factor: 7.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.